A new method and system can be implemented to identify, analyze and display hierarchies of condition-specific gene, network or pathway activities or aberrations. Methods are also presented related to biomarker and drug-target identification and diagnosing new patients or samples with diseases or disease subtypes. Further, methods are presented related to predicting patient survival or response to treatment. Finally, methods are presented that can provide information of biological agricultural or medical interest. Methods provided herein include methods of making a multidimensional multiscale module map for identifying, analyzing and displaying hierarchies of network or pathway activities, the multidimensional multiscale map, and systems for discussing genomic features of a subject or sample with the multiscale module map.

The present invention in general relates to an immediate-release pharmaceutical composition containing ketoprofen lysine salt and mannitol. In particular, the present invention relates to an immediate-release pharmaceutical composition in the form of tablet. The invention also provides a process for manufacturing such composition.

A medical chewing gum including gum base polymers and one or more cannabinoids as an active pharmaceutical ingredient, the gum base polymers including polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer.

A method for preparing granules a slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

The present invention relates to a solid unit dosage form for oral administration (tablet or granules) containing a solid dispersion of valsartan and sacubitril in a polymeric matrix. The solid dispersion is prepared by hot-melt extrusion and may contain the active ingredients preferably in a non-crystalline state. LCZ696, (pseudo)polymorphic forms thereof as well as the individual drugs, e.g. valsartan disodium and sacubitril monosodium, may be subjected to the hot-melt extrusion process.

The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.

An orally disintegrating tablet combinable with a variety of drugs and exhibits excellent disintegrating properties in an oral cavity but having strength and the like allowing ability to form a tablet. The annular orally disintegrating tablet containing a drug and a disintegrating agent; and having a hole in a central portion making it annular. The content of the disintegrating agent relative to total weight is 2% to 50% by weight. It exhibits excellent disintegrating properties, i.e., when a gradient of disintegrating time (seconds) of the tablet with respect to tableting pressure (kN) upon compression-forming is defined as a and a gradient of disintegrating time (seconds) of a disk-shaped orally disintegrating tablet with respect to tableting pressure (kN) upon compression-forming is defined as b, the disk-shaped orally disintegrating tablet having the same weight and external diameter as the annular orally disintegrating tablet the ratio (a/b) is 0.90 or less.

To provide a mirabegron-containing tablet that maintains the amorphous form of mirabegron even after long-term storage. Also, to provide a mirabegron-containing pharmaceutical preparation that can maintain the purity of mirabegron while preventing the generation of related substances at the time of storage, a method for producing a mirabegron-containing pharmaceutical preparation, and a method for producing a mirabegron-containing granulated product. According to an embodiment of the present invention, there is provided a mirabegron-containing pharmaceutical preparation containing mirabegron, hypromellose, and polyvinylpyrrolidone. The mirabegron-containing pharmaceutical preparation may contain a spray-dried granulated product containing the mirabegron, the hypromellose, and the polyvinylpyrrolidone.